| Publication: Circulation 2025;152:e114–e218 | Jones DW, Ferdinand KC, Taler SJ et al. | Validity: Replaces the 2017 guideline |
2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA / PCNA / SGIM
TABLE OF CONTENTS
1. Guideline Overview and Novelties
2. Blood Pressure Classification
• In-Office Measurement — Out-of-Office Monitoring (ABPM/HBPM)
• White Coat / Masked Hypertension
• Secondary Hypertension Screening
4. Drug Initiation Threshold & CVD Risk Assessment
• First-Line Agents and Combination Therapy
• BP Goals
• Medication Adherence Strategies
• Diabetes | CKD | Heart Failure | Stroke | Pregnancy | Elderly
9. Hypertensive Emergency and Severe Hypertension
10. Team-Based Care and Follow-Up
1. Guideline Overview and Novelties
The 2025 AHA/ACC Hypertension Guideline is an updated clinical practice document that replaces the 2017 guideline, based on a comprehensive literature review from December 2023 to June 2024. The guideline is designed for all clinicians managing hypertension in primary care and specialty settings.
Top Take-Home Messages of the 2025 Guideline
- High blood pressure is the most common and modifiable risk factor for cardiovascular diseases. The general BP goal for all adults is <130/80 mmHg.
- Clinicians should collaborate with community leaders and health systems to screen all adults in their communities.
- Multidisciplinary team-based care is effective in evaluating access to medications and overcoming individual barriers.
- BP classification: Normal <120/80, Elevated 120-129/<80, Stage 1 HTN 130-139/80-89, Stage 2 HTN ≥140/≥90 mmHg.
- Lifestyle modifications (DASH diet, sodium restriction, weight loss, exercise, alcohol reduction) are strongly recommended for all adults.
- Pharmacological treatment is recommended for all adults with an average BP of ≥140/90 mmHg, and selected adults with a BP of ≥130/80 mmHg along with CVD, diabetes, CKD, or a PREVENT score of ≥7.5%.
- Single-pill combination therapy (SPC) should be preferred in Stage 2 HTN.
- Home BP monitoring + integration with a multidisciplinary team is an important tool that improves BP control.
- Severe hypertension (>180/120, no target organ damage) should be managed by initiating oral medication in an outpatient setting.
- When SBP ≥160 / DBP ≥110 mmHg is confirmed in pregnant women, medication should be initiated within 30-60 minutes.
From 2017 to 2025: Key Changes
| Topic | 2017 Recommendation | 2025 Recommendation |
|---|---|---|
| Terminology | Hypertensive urgency | Severe hypertension |
| Primary aldosteronism screening | Screen if hypokalemia is present | Screen in resistant HTN even without hypokalemia (COR 1) |
| Potassium-based salt substitute | Not specified | Can be beneficial if there is no CKD and no use of K+-sparing drugs (COR 2a) |
| ACEi/ARB in Diabetes | Could be considered if CKD with albuminuria is present | Recommended if CKD (eGFR<60 or albuminuria ≥30 mg/g) is present (COR 1) |
| RAASi in CKD | ACEi is a reasonable option (COR 2a) | ACEi or ARB is recommended in eGFR<60 + albuminuria ≥30 mg/g (COR 1) |
| Acute ICH — SBP 150-220 | Target <140 mmHg (COR 2a) | Lower SBP to 130-140 mmHg, discontinue drug if <130 (COR 2a) |
| BP post-EVT in ischemic stroke | Not specified | Lowering SBP to <140 mmHg post-reperfusion may cause HARM (COR 3) |
| Dementia prevention | Lowering BP is reasonable (COR 2a) | SBP target <130 mmHg is recommended (COR 1, Level A) |
| Pregnancy — chronic HTN | Not specified | Medication should be initiated targeting <140/90 mmHg (COR 1) |
| Contraindicated drugs in pregnancy | ACEi, direct renin inhibitors | Additionally: atenolol, ARB, nitroprusside, MRA (COR 3 Harm) |
| Renal denervation (RDN) | Not specified | Multidisciplinary team evaluation is required in resistant HTN (COR 1) |
| In-hospital severe HTN management | Not specified | Do not administer additional IV/oral agents if there is no target organ damage (COR 3 Harm) |
ACEi: Angiotensin-converting enzyme inhibitor, ARB: Angiotensin receptor blocker, BP: Blood pressure, CKD: Chronic kidney disease, COR: Class of Recommendation, CVD: Cardiovascular disease, DBP: Diastolic blood pressure, eGFR: Estimated glomerular filtration rate, ICH: Intracerebral hemorrhage, MRA: Mineralocorticoid receptor antagonist, PREVENT: Predicting Risk of CVD EVENTs, RAASi: Renin-angiotensin-aldosterone system inhibitor, RDN: Renal denervation, SBP: Systolic blood pressure
2. Blood Pressure Classification
The guideline maintains the 2017 classification. BP classification should be based on an average of at least 2 readings obtained on two or more occasions.
| BLOOD PRESSURE CATEGORY | SYSTOLIC (mmHg) | DIASTOLIC (mmHg) | |
|---|---|---|---|
| NORMAL | < 120 | and | < 80 |
| ELEVATED | 120–129 | and | < 80 |
| HYPERTENSION STAGE 1 | 130–139 | or | 80–89 |
| HYPERTENSION STAGE 2 | ≥ 140 | or | ≥ 90 |
| HYPERTENSIVE CRISIS (Evaluate immediately!) | > 180 | and/or | > 120 |
In-Office BP Measurement — Correct Technique
- No caffeine, exercise, or smoking 30 min before measurement.
- 5 min quiet sitting; back supported, feet flat on the floor.
- Arm at heart level, no talking.
- At least 2 measurements, 1 min apart; take the average.
- Measure from both arms at the first visit.
- Correct cuff size: should encircle 80% of the arm.
- Avoid wearable devices (smartwatches, etc.) — insufficient accuracy.
Out-of-Office BP Monitoring
- ABPM (24-hour ambulatory BP): Significant if daytime ≥130/80, nighttime ≥110/65, 24-hour ≥125/75 mmHg.
- HBPM (Home BP monitoring): Measure in the morning before medication and in the evening before dinner; significant if ≥135/85 mmHg.
- Suspected White Coat HTN: In-Office ≥130/80 + ABPM/HBPM <130/80 → confirmatory test.
- Suspected Masked HTN: In-Office <130/80 + ABPM/HBPM ≥130/80 → high CVD risk.
- If SBP/DBP ≥160/100, treatment should be intensified without waiting for out-of-office monitoring.
3. Diagnostic Evaluation
3.1. Patient Evaluation — Laboratory and Diagnostic Tests
- Basic Laboratory Tests:
- Fasting blood glucose or HbA1c
- Lipid panel (LDL, HDL, TG)
- Electrolytes (Na, K, Cl, bicarbonate)
- Serum creatinine + eGFR calculation
- Spot urine albumin/creatinine ratio
- Urinalysis (dipstick + microscopy)
- TSH (in suspected secondary HTN)
- ECG and Imaging:
- ECG: Evaluation for left ventricular hypertrophy
- Echocardiography: If clinically indicated
- Fundoscopy: Suspected retinal damage
- Renal Doppler: Suspected renovascular HTN
- 24-hour urine aldosterone/cortisol: Secondary HTN
- Sleep study: Suspected obstructive sleep apnea
3.2. Secondary Hypertension Screening
Secondary hypertension can be seen in 5-25% of adult hypertensive patients. Further investigation should be done if any of the following clinical clues are present:
| Secondary Cause | Prevalence | Screening Indications | Screening Test |
|---|---|---|---|
| Obstructive Sleep Apnea (OSA) | 25–50% | Snoring, daytime sleepiness, resistant HTN, excess weight | STOP-Bang Questionnaire; overnight oximetry |
| Chronic Kidney Disease (CKD) | 14% | Diabetes, hematuria, nocturia, low eGFR, family history | Electrolytes, creatinine, microalbuminuria, renal USG |
| Primary Aldosteronism | 5–25% | Resistant HTN (even without hypokalemia!), OSA, adrenal incidentaloma, young age HTN or family history of stroke | Plasma aldosterone/renin activity ratio (≥30 is positive) |
| Drug/Substance-Induced | 2–20% | NSAIDs, oral contraceptives, cyclosporine, sympathomimetics, cocaine, alcohol | Medication list review; urine toxicology |
| Renovascular HTN | 0.1–5% | Resistant HTN, sudden BP spike, flash pulmonary edema, <30 years HTN (female, fibromuscular dysplasia) | Renal duplex Doppler; MR angiography |
| Pheochromocytoma | <0.6% | Paroxysmal HTN, crises, triad of headache+sweating+palpitations | 24-hour urine fractional metanephrines |
| Cushing’s Syndrome | <0.1% | Rapid weight gain, central obesity, proximal muscle weakness, hyperglycemia | 1 mg Dexamethasone suppression test |
| Hypothyroidism/Hyperthyroidism | <1% | Related symptoms | TSH, free T4 |
| Aortic Coarctation | 0.1% | Young age (<30 y), high upper extremity BP | Echocardiography |
Primary Aldosteronism Screening — Important Point: The presence of hypokalemia is no longer a prerequisite for the screening decision. Screening is recommended in all patients with resistant hypertension. You do not need to discontinue antihypertensive drugs other than MRAs (spironolactone/eplerenone) before screening. During screening, MRAs must be discontinued at least 4 weeks in advance.
4. Drug Initiation Threshold & CVD Risk Assessment
The 2025 guideline uses the PREVENT™ (Predicting Risk of CVD EVENTs) model instead of the ASCVD score. The critical threshold is ≥7.5% ten-year CVD risk.
| BLOOD PRESSURE | CONDITION | RECOMMENDATION (COR/LOE) |
|---|---|---|
| ≥ 140/90 mmHg | All adults | Initiate drug + Lifestyle modification (COR 1) |
| ≥ 130/80 mmHg | CVD / stroke / diabetes / CKD or PREVENT ≥ 7.5% | Initiate drug + Lifestyle modification (COR 1) |
| ≥ 130/80 mmHg | PREVENT < 7.5% (low risk) | Lifestyle modifications first for 3-6 months; if BP remains ≥130/80, add drug (COR 1) |
| 120-129 / < 80 mmHg | Elevated BP (all adults) | Lifestyle modifications only |
- Goal: <130/80 mmHg for all adults. Achieving <120 mmHg SBP is encouraged in cases with high CVD risk.
- About the PREVENT Score:
- Replaced the older ASCVD (Pooled Cohort Equations) model.
- Includes age, sex, BP, smoking, lipids, diabetes, CKD, obesity, and social determinants.
- Online calculator: American Heart Association PREVENT calculator.
- Threshold: ≥7.5% = high risk → initiate drug at 130/80 mmHg.
5. Lifestyle Modifications
Lifestyle modifications are strongly recommended for all adults (COR 1). Their effects on lowering blood pressure are summarized in the table below:
| Lifestyle Modification | Recommendation | Approximate SBP Reduction |
|---|---|---|
| Weight management | Aim for normal BMI (18.5–24.9 kg/m²) | 5 mmHg |
| DASH diet | Fruits, vegetables, whole grains, low-fat dairy; restrict sodium and saturated fat | 11 mmHg |
| Sodium restriction | < 1,500 mg/day is ideal; even a 1,000 mg reduction is beneficial | 5–6 mmHg |
| Physical activity | 90–150 min moderate aerobic per week; or 75 min vigorous | 5–8 mmHg |
| Alcohol | Alcohol restriction | 4 mmHg |
| Stress management | Mindfulness, relaxation techniques, psychosocial support | Variable |
| Potassium-based salt substitute (NEW 2025) | Can be used if no CKD and no K+-reducing drugs are used (COR 2a) | ~5 mmHg (estimated) |
Practical Tips for Sodium Restriction:
- Label reading: ≤ 140 mg/serving = low sodium
- Watch out for the ‘Salty 6’: bread/rolls, pizza, sandwiches, cold cuts/deli meats, soup, burritos
- Hidden sodium: cheese, canned vegetables, ketchup, restaurant meals
- NSAID use increases sodium retention → avoid if possible
- Alcohol, caffeine, decongestants (phenylephrine, pseudoephedrine) raise BP → use with caution
6. Pharmacological Treatment
6.1. First-Line Agents
| Drug Class | Starting Dose | Daily Frequency | Key Warnings |
|---|---|---|---|
| Thiazide-Type Diuretics | |||
| Chlorthalidone (preferred) | 12.5–25 mg | 1x | Longer half-life; more potent than HCTZ. Monitor for hyponatremia, hypocalcemia, hypokalemia. |
| Hydrochlorothiazide (HCTZ) | 25–50 mg | 1x | Monitor glucose, uric acid, calcium. |
| Indapamide | 1.25–2.5 mg | 1x | Less metabolic effect than HCTZ. |
| ACE Inhibitors (ACEi) | |||
| Lisinopril | 10–40 mg | 1x | CONTRAINDICATED in pregnancy. Do not combine ACEi+ARB. Monitor K+, creatinine. |
| Ramipril | 2.5–20 mg | 1-2x | Do not use if history of angioedema. |
| Enalapril | 5–40 mg | 1-2x | |
| ARB (Angiotensin Receptor Blocker) | |||
| Losartan | 50–100 mg | 1-2x | CONTRAINDICATED in pregnancy. Do not combine ACEi+ARB. |
| Valsartan | 80–320 mg | 1x | |
| Olmesartan | 20–40 mg | 1x | |
| Calcium Channel Blocker (DHP-CCB) | |||
| Amlodipine | 2.5–10 mg | 1x | Ankle edema (more common, especially in women). Combination with RAASi reduces edema. |
| Nifedipine LA | 30–90 mg | 1x |
6.2. Alternative and Second-Line Agents
| Drug Class | Notes |
|---|---|
| Non-DHP CCB (Diltiazem ER, Verapamil SR) | Do not use routinely with beta blockers (bradycardia, AV block risk). Do not use in HFrEF. CYP3A4 substrate/inhibitor. |
| Aldosterone Antagonists (Spironolactone, Eplerenone) | Preferred in primary aldosteronism and resistant HTN. Highly effective as a 4th agent in resistant HTN. Caution if eGFR <45. Spironolactone: gynecomastia, erectile dysfunction risk. |
| Loop Diuretics (Furosemide, Torsemide) | Preferred in symptomatic HF. Use instead of thiazides when eGFR <30 mL/min. |
| Beta Blockers | Not first-line (unless coronary disease or HF present). Avoid abrupt discontinuation. Bisoprolol/metoprolol succinate preferred in HFrEF. Atenolol is contraindicated in pregnancy (NEW 2025). |
| Alpha-1 Blockers (Doxazosin) | Orthostatic hypotension risk. Beneficial in BPH. Not first-line. |
| Direct Renin Inhibitor (Aliskiren) | Do not combine with ACEi or ARB. Contraindicated in pregnancy. |
| Aprocitentan (Dual Endothelin Receptor Antagonist — NEW) | Add-on therapy for inadequately controlled resistant HTN. Fluid retention in the first 4-6 weeks. |
| Clonidine oral/patch | Last resort. Abrupt cessation can lead to hypertensive crisis. Prominent CNS side effects in the elderly. |
| Hydralazine + Isosorbide Dinitrate | Beneficial if dialysis-requiring CKD or ACEi/ARB intolerance. Especially recommended for Black patients with HFrEF. |
6.3. Drug Selection Strategy — Algorithm
- Stage 1 HTN — Monotherapy or SPC:
- Can start with a single agent; especially in cases close to target BP.
- Preferred: Thiazide-type diuretic, ACEi, ARB, or DHP-CCB.
- If response is insufficient, increase dose or add a second agent.
- Titrate slowly in elderly patients with orthostatic risk.
- High-risk Stage 1 (ASCVD >7.5%, Black race) → Initiate combination with SPC.
- Stage 2 HTN — SPC Preferred:
- Agents from two different classes; single-pill combination (SPC) preferred.
- SPC: better adherence, faster BP control.
- Recommended combination: RAASi + thiazide-type diuretic or DHP-CCB.
- If response is insufficient, add a third agent.
- Combinations to Avoid:
- ACEi + ARB: Risk of hyperkalemia + AKI (CONTRAINDICATED).
- ACEi or ARB + Aliskiren: Same mechanism, high risk.
- Verapamil/Diltiazem + Beta blocker: Bradycardia, AV block.
- Two different BBs together: Restrict to isolated monotherapy.
- Useful Combinations:
- RAASi + Thiazide: RAASi reduces the hypokalemic effect of the diuretic.
- DHP-CCB + RAASi: CCB’s ankle edema is reduced by RAASi.
- Thiazide + K+-sparing diuretic: Controls thiazide-induced hypokalemia.
- Thiazide + Loop diuretic: Acceptable in selected conditions.
6.4. BP Goals
| Patient Group | SBP Goal | DBP Goal | Level of Evidence |
|---|---|---|---|
| High CVD risk (PREVENT ≥7.5%) | < 130 mmHg (ideal: encourage < 120 mmHg) | < 80 mmHg | COR 1, Level A |
| Low CVD risk (PREVENT < 7.5%) | < 130 mmHg (reasonable) | < 80 mmHg (reasonable) | COR 2b |
| CKD (eGFR <60 or albuminuria ≥30) | < 130 mmHg | < 80 mmHg | COR 1, Level A |
| Diabetes | < 130 mmHg | < 80 mmHg | COR 1 |
| Post-Stroke / TIA | < 130/80 mmHg | < 80 mmHg | COR 1, Level A |
| Dementia prevention | < 130 mmHg SBP | — | COR 1, Level A |
| Pregnancy (chronic HTN) | < 140/90 mmHg | — | COR 1 |
| Institutionalized care / Limited life expectancy | Shared decision-making | — | Expert opinion |
6.5. Medication Adherence Strategies
- Prefer 1 dose daily (adherence is higher compared to multiple doses).
- Prescribe SPC (single-pill combination) — reduces pill burden, increases adherence.
- Synchronize prescription refill tracking with medication appointments.
- Use telehealth, SMS reminders, smartphone apps.
- Screen for stress, anxiety, depression → non-adherence is higher in these groups.
- Provide simple, visual materials if health literacy is low.
- If non-adherence is detected, converse without judgment; understand the patient’s perspective.
7. Special Populations
7.1. Diabetes + Hypertension
- BP goal: < 130/80 mmHg (COR 1).
- If CKD eGFR <60 or albuminuria ≥30 mg/g is present: ACEi or ARB is recommended (COR 1) → delays progression of diabetic kidney disease.
- If mild albuminuria (<30 mg/g) is present: ACEi/ARB could be considered (COR 2a).
- Do not combine ACEi + ARB.
- Thiazide-type diuretic or DHP-CCB if RAASi is contraindicated.
7.2. Chronic Kidney Disease (CKD)
- BP Goal and Drug Selection:
- SBP < 130 mmHg target (COR 1, Level A).
- eGFR <60 + albuminuria ≥30 mg/g: RAASi (ACEi or ARB — not both) is recommended.
- Check electrolytes and eGFR 2-4 weeks after initiating ACEi/ARB.
- eGFR drop > 30% → reduce or discontinue drug; perform further investigation.
- ACEi/ARB can be continued even at eGFR <30 (NEPHRON-D trial).
- Prefer loop diuretic over thiazide at eGFR <30.
- Monitoring Parameters:
- Potassium: Hyperkalemia monitoring (especially in RAASi + K+-sparing combinations).
- Serum creatinine and eGFR: Every 2-4 weeks (upon dose change).
- Aldosterone/renin ratio: In suspected primary aldosteronism.
- Spot urine albumin/creatinine: Annual follow-up.
- Minimize systolic blood pressure variability.
7.3. Heart Failure (HFrEF) + Hypertension
| Drug Class | Indication | Notes |
|---|---|---|
| BB (bisoprolol, carvedilol, metoprolol succinate) | All HFrEF including asymptomatic | Use the 3 BBs that reduce cardiac mortality. |
| MRA (spironolactone, eplerenone) | Symptomatic HFrEF; eGFR >30 + K+ <5 | Reduces morbidity/mortality. |
| ARNi (Sacubitril/Valsartan) | NYHA II-III HFrEF | Preferred over ACEi/ARB; reduces mortality. |
| ACEi or ARB | If ARNi cannot be used | |
| SGLT2 inhibitor | Symptomatic HFrEF (whether diabetic or not) | Reduces hospitalizations and CV mortality. |
| Hydralazine + Isosorbide dinitrate | Black race NYHA III-IV; those unable to use ARNi/ACEi/ARB |
7.4. Cerebrovascular Disease + Hypertension
| Condition | BP Goal | Drug / Approach |
|---|---|---|
| Post-chronic stroke/TIA (stable) | SBP/DBP < 130/80 mmHg (COR 1, A) | Thiazide, ACEi or ARB preferred |
| Acute ICH — SBP 150–220 mmHg | Lower SBP to 130–140 mmHg immediately; discontinue drug if <130 (COR 2a, A) | Titratable IV agent; nicardipine, labetalol |
| Acute ICH — SBP > 220 mmHg | Lower cautiously to 160-180 mmHg (COR 2a) | Do not lower SBP <130 — harmful! |
| Acute ischemic stroke — for IV tPA | SBP < 185 / DBP < 110 mmHg (before tPA) and < 180/105 for 24 hours (COR 1, B-NR) | Labetalol, nicardipine |
| Post-EVT (endovascular therapy) | ≤ 180/105 mmHg, for 24 hours (COR 2a) | Lowering SBP < 140 causes HARM (COR 3 Harm) — NEW |
| Acute ischemic stroke (SBP < 220, no tPA/EVT) | Initiating in the first 48-72 hours is ineffective (COR 3 No Benefit) | Treat if comorbidity requires it |
| Dementia prevention | SBP < 130 mmHg (COR 1, Level A) — NEW | All first-line agents are suitable |
7.5. Pregnancy and Hypertension
- BP Management in Pregnancy — 2025 New Recommendations:
- SBP ≥160 or DBP ≥110 mmHg → confirm within 15 min → initiate drug within 30-60 min (COR 1) — lower to <160/<110.
- Chronic HTN (pre-pregnancy or diagnosed <20th week) → treat with a goal of <140/90 mmHg (COR 1 — NEW).
- Recommend low-dose aspirin to those at risk of preeclampsia (COR 1 — NEW).
- CONTRAINDICATED Drugs in Pregnancy (COR 3 Harm — 2025 updated):
- ACEi, ARB, direct renin inhibitors
- Atenolol (NEW — added 2025)
- Nitroprusside (NEW)
- Mineralocorticoid receptor antagonists (MRA) (NEW)
- SAFE Drugs in Pregnancy:
- Labetalol (IV and oral), hydralazine (IV), nicardipine (IV)
- Oral: methyldopa, nifedipine LA
7.6. Elderly Patients and Resistant Hypertension
- Elderly Patient (≥65 Years):
- BP goal: < 130/80 mmHg; frail patient → shared decision-making.
- Orthostatic hypotension screening: Measurement at 1st and 3rd minute after standing.
- Intensive BP lowering is still beneficial in orthostatic HTN, can be maintained with careful monitoring.
- Combined BP variability + hypotensive episodes are associated with cognitive decline.
- When initiating medication, use low dose, slow titration; reduce the iatrogenic fall risk.
- Diuretics should be used more cautiously regarding fluid loss.
- Resistant Hypertension:
- Definition: Target BP cannot be reached with the maximum tolerated 3 drugs (including a diuretic).
- Before true resistance is confirmed: rule out non-adherence, white coat effect, drug/substance-induced HTN.
- Review the entire medication list; remove or adjust drugs that affect BP (COR 1).
- Investigate secondary causes (especially primary aldosteronism, OSA).
- Add spironolactone as the 4th agent → the most effective add-on agent.
- Renal denervation (RDN): In selected cases in resistant HTN; multidisciplinary team evaluation (COR 1).
- Shared decision-making; discuss pros/cons of RDN vs. medical therapy.
8. Hypertensive Emergency and Severe Hypertension
| Definition | BP Value | Goal / Approach | Recommended Drugs |
|---|---|---|---|
| Hypertensive Emergency Target organ damage is PRESENT | SBP/DBP > 180/120 + Encephalopathy, papilledema, acute MI, AKI, aortic dissection | Lower by 10–20% in the first 1 hour, to ≤160/100 mmHg in the first 6 hours. Intensive care unit monitoring | IV nicardipine, labetalol, esmolol, nitroprusside (aortic diss.), hydralazine (pregnancy) |
| Severe Hypertension Target organ damage is ABSENT | SBP/DBP > 180/120 | Initiate/intensify oral medication in the outpatient setting instead of the emergency room | Oral amlodipine, clonidine (cautious), captopril; routine IV agent is not recommended |
| In-hospital incidental severe HTN (non-cardiac admission, no target organ damage) | SBP/DBP > 180/120 | DO NOT acutely lower BP with an additional IV or oral agent (COR 3 Harm — NEW) | Treat underlying cause; continue regular medications |
Important Warning — 2025 New Recommendation: For asymptomatic severe hypertension (>180/120 mmHg) in adult patients admitted for non-cardiac reasons with no target organ damage, acute BP lowering using an additional intravenous or oral antihypertensive agent is not recommended (COR 3 Harm). This approach can cause harm and provides no benefit.
9. Team-Based Care and Follow-Up
9.1. Multidisciplinary Team-Based Care (COR 1, Level A)
| Team Member | Role / Responsibility |
|---|---|
| Primary Care Physician / Specialist | Routine and complex HTN management; primary care issues |
| Cardiologist / Nephrology / HTN Specialist | Secondary HTN, resistant HTN, complex cases with CVD comorbidities |
| Clinical Pharmacist | Comprehensive medication management, drug-drug interactions, patient education |
| Nurse (In-office, home care, community health) | BP measurement, medication reconciliation, lifestyle education, adherence monitoring |
| Dietitian | Assessing dietary habits, DASH diet counseling |
| Social Worker | Identifying and resolving psychosocial, cultural, financial barriers |
| Community Health Worker | Address social determinants of health; community screening |
9.2. Follow-Up After Treatment Initiation / Intensification
- Monthly follow-up for uncontrolled HTN patients with newly initiated medication or changed doses until target BP is reached (COR 1, B-R).
- Medication adherence + BP response should be evaluated at every visit.
- Electrolyte + creatinine check 2-4 weeks after RAASi initiation.
- Review home BP monitoring (HBPM) data prior to the clinical visit.
- EHR and patient registries: Use the registry system to identify uncontrolled HTN patients.
- Telehealth (synchronous or asynchronous): An effective tool for remote monitoring + medication titration (COR 2a, B-R).
9.3. Social Determinants of Health (SDOH) and Health Equity
Socioeconomic status, access to food, housing conditions, exposure to stress and discrimination affect BP control. In Black adults, hypertension begins earlier, is more severe, and complications are seen more frequently. Thiazide-type diuretics and CCB monotherapy may be more effective than ACEi/ARB in this group.
- Screen for SDOH barriers in every patient (transportation, medication access, health literacy, financing).
- Consider initial combination therapy (thiazide + CCB) first in Black patients.
- Community-based health workers and team care are effective in reducing racial disparities in BP control.
- Clinical decision support systems (EHR) and patient registries should be used to proactively identify high-risk patients.
10. Quick Reference Card — Summaries for the Clinician
When Do I Initiate Medication?
✔ BP ≥ 140/90: For everyone ✔ BP ≥ 130/80 + CVD/DM/CKD/PREVENT≥7.5% ⚠ BP 130-139 + low risk: Lifestyle first for 3-6 months
What Are My BP Goals?
- General goal: < 130/80 mmHg
- High risk: < 130 mmHg; ideal < 120 mmHg
- Pregnancy (chronic HTN): < 140/90 mmHg
- Post-Stroke/TIA: < 130/80 mmHg
What Are My First-Choice Drugs?
- Thiazide-type diuretic (chlorthalidone preferred)
- ACEi or ARB (not together!)
- DHP-CCB (amlodipine)
- Stage 2 → Prefer SPC (single-pill combination)
When Do I Investigate Secondary HTN?
- Resistant HTN (no control with 3 drugs)
- Young age (<30 y), sudden onset
- Hypokalemia (drug-induced or spontaneous)
- Adrenal incidentaloma
- Sleep apnea, family history
- Paroxysmal HTN + sweating + palpitations
Caution in Pregnancy!
- CONTRAINDICATED: ACEi, ARB, Atenolol, MRA, Nitroprusside
- SAFE: Labetalol, hydralazine, methyldopa, nifedipine LA
- SBP ≥160 / DBP ≥110 → medication within 30-60 min!
Severe HTN in Hospital — 2025 Change
- NO target organ damage → DO NOT give additional IV/oral agents (COR 3 Harm)
- Continue regular medications; treat the underlying cause
This document is a summary guide prepared for healthcare professionals based on the 2025 AHA/ACC Hypertension Guideline (Circulation 2025;152:e114–e218). Clinical decisions should be based on the original guideline text and individual patient assessment.Share
